From University of California · · 1m 10s
Semaglutide Slows Aging in HIV Patients
New study shows GLP-1 drug reduces biological aging markers in HIV patients.
In brief
New study shows GLP-1 drug reduces biological aging markers in HIV patients. Semaglutide slowed biological aging by 9% in HIV patients with lipohypertrophy, measured by epigenetic clocks. Originally reported by University of California.
New Study Finds
Semaglutide slowed biological aging across multiple epigenetic clocks in HIV patients.
Clinical Trial Details
108 adults with HIV-associated lipohypertrophy received weekly semaglutide or placebo injections.
Epigenetic Clocks
Researchers tracked DNA methylation changes using DunedinPACE and PCGrimAge epigenetic clocks.
Key Findings
Semaglutide slowed biological aging by 9% and reduced mortality risk markers in HIV patients.
Mechanisms
GLP-1 drugs reduced inflammation and visceral fat to slow aging processes in HIV patients.
Lead Researcher
Michael Corley, Ph.D., UC San Diego associate professor, led the study on aging in HIV.
Broader Implications
Findings may benefit general population due to shared aging mechanisms in HIV and healthy individuals.
Related Study
Pilot study reduced aging rate in 42% of HIV patients with fatty liver disease after 24 weeks.
Future Research
Larger trials needed to confirm effects and determine optimal dosing for aging interventions.
The headline
Semaglutide slowed biological aging by 9% in HIV patients with lipohypertrophy, measured by epigenetic clocks.
